This clinical trial will be performed on 30 RA patients, who referred to Imam Reza and Qaem Medical Centers of Mashhad, Iran. Patients will be divided into two groups regard to random block method.
The inclusion criteria are as follows: 1) meeting the 2010 ACR/EULAR criteria; 2) ≥18 years of age; and 3) DAS-28-ESR < 3.2. The exclusion criteria are:: 1) known liver disease; 2) elevated transaminases two months before the study; 3) previous history of myopathy; 4) pregnancy; 5) breastfeeding; 6) use of lipid-lowering agents; and 7) being eligible for taking lipid-lowering agents according to the National Cholesterol Education Program (NCEP).
Patients will be divided into two groups: 1) the intervention group receiving 40 mg of atorvastatin, and 2) the control group. Response to treatment and the clinical status of patients will be evaluated using Disease Activity Score (DAS-28) and Visual Analogue Scale (VAS) at weeks zero, four, eight, and twelve, based on the 2010 ACR/EULAR Criteria by two rheumatologists who are blinded to the intervention. Disease activity and laboratory parameters including erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP), DAS-ESR,DAS- hs-CRP , high-density lipoprotein (HDL), low-density lipoprotein (LDL) and liver function test (LFT) will be measured in both groups.